| Actual |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Debt Relief > Joint IVAs: How Do They Work? |
|
Actual - Joint IVAs: How Do They Work?
Joint IVAs as they are referred to, allow two people to unite their resources and pool their debts, enabling them to qua According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product lify for an IVA when it might otherwise be beyond their reach. In reality the insolvency practitioner who acts as a nom ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in nee for the two people concerned, will actually propose two individual IVAs. However, once the IVAs are accepted by the lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. reditors, the insolvency practitioner supervises the two cases as one, which in turn creates a substantial saving on fee here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe charged to the creditors. These saving are passed on to the creditors, which in turn means the creditors will receive a d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro greater amount of money from the IVA fund. Joint IVAs provide an alternative solution to bankruptcy, especially in case ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc where two 'stand alone' IVAs may not be possible. For an IVA to be acceptable to creditors the debtor's circumstances easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi must meet certain prearranged conditions.
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically debt must be owed to at least 4 different creditors.
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ t have a disposable income sufficiently high to be able to repay at least 25% of the debt, plus costs.
Here ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi is an example of a set of circumstances where a Joint IVA might suit: Imagine a couple living together. Each has a pers ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a nal unsecured debt of ?12,500 owed to 4 creditors. Let's also imagine the monthly repayments of these debts adds up to ? dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod 00 each person, or ?600 between them. One works full time, the other part time. Together they generate enough income to cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin over their joint expenditure, but after all their costs are deducted from their joint incomes, they are left with just ? tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen 350. Insufficient to maintain their required debt repayments. Individually they would not have sufficient debt to quali t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel y for an IVA, but together their debts amount to ?25,000 which is above the required threshold. Also, neither would be ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ble to afford the necessary minimum repayment into an IVA on their own, but by working as a team, pooling both the debts y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products and the disposable income, a joint IVA becomes a distinct possibility. A joint IVA does not require the t . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de o people involved to be married. It can be any two people who share the same living costs. Getting into elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ebt as a couple is easy, but it's nice to know there is a debt solution that offers you a way out together tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Online Auctions - 10 Secrets You Should Know Before Bidding How To Increase Your Traffic Flow To Your Site & Get Indexed Faster! 3 Ways to Get Targeted Traffic to Your Site... Now
|